Nektar Therapeutics has dropped another 8.5% this week to $60.97, compounding a bruising month that has now erased 17.6% — and the most telling shift from seven days ago is not in the short book but on the Street, where Wedbush slashed its price target this morning.
The analyst action is the standout change since last week's note. Wedbush cut its target from $80 to $50 — a 37.5% reduction — while keeping a Neutral rating, making it the most bearish published target in the recent coverage set. That stands in sharp contrast to BTIG, which has twice reiterated a Buy with a $178 target in the past two weeks, and to the mean consensus target of $141.40, which now implies a return of more than 130% from current levels. The spread between the Wedbush floor and the BTIG ceiling is extraordinary, reflecting genuine disagreement about pipeline execution risk. The Eli Lilly legal dispute over REZPEG hangs over the bear case; the bull case rests on Phase 2 readouts for rezpegaldesleukin and NKTR-0165 that could catalyse partnership conversations. With next earnings not until November 11, the battleground is clinical news flow, not quarterly numbers.
Options traders turned meaningfully more defensive on Tuesday. The put/call ratio hit 0.34, more than three standard deviations above its 20-day average of 0.25 — the most elevated defensive reading in the options market for months. That single-session spike is the clearest evidence that some holders are now buying protection rather than conviction. For context, the PCR had been running in a tight band around 0.23-0.27 for most of August and into mid-September; Tuesday's 0.34 print broke sharply from that range. The 52-week high on the PCR is 0.91, so the position is not historically extreme, but the sudden move after weeks of calm is worth noting.
Short positioning has shifted modestly compared to last week's note, but the structural story holds. Short interest rose 4.4% on the week to 30.5% of the free float — around 6.2 million shares — reversing some of the gradual unwind that had taken the book down from roughly 6.4 million shares in early August. That said, the borrow market remains uncrowded. Availability is running at 167% of outstanding short interest, tighter than the 217% level cited in last week's note but still well within the "normal" range, and above the 52-week low of 148%. Cost to borrow has risen 63% on the week to 0.52%, a notable acceleration, though in absolute terms it remains low. The combination of rising short interest, tightening availability, and climbing borrow costs is directionally more charged than it was seven days ago — but not yet at levels that would signal a squeeze setup.
Institutional positioning provides some ballast. FMR (Fidelity) holds 14.8% of shares and added over 760,000 shares in the most recent reported quarter. BlackRock built an outsized position, adding 2.25 million shares to reach 8.6%. Both moves suggest large passive and active holders were buying into weakness earlier this year. On the activist register, no 13D filer is present — all 13D/G filings are passive 13G designations, with several holders including Samlyn Capital and TCG Crossover having exited entirely in recent months. Stakes are as-last-disclosed around the 5% threshold; a holder dropping below 5% may not file again. Insider activity has been exclusively sales, though the bulk of executive selling from CEO Howard Robin and Chief R&D Officer Zalevsky in June was conducted under pre-arranged 10b5-1 plans, limiting the signal from those transactions. A smaller discretionary sale by Robin in August at $71.98 — now 15% above the current price — is harder to dismiss entirely.
The ORTEX short score, at 71.8, sits near its highest reading of the past two weeks and ranks in the bottom 12th percentile of the universe — a signal that the data composite flags elevated short pressure. With Wedbush now at $50, the stock trading at $60.97, and the November earnings date still six weeks away, the next concrete pivot will be any clinical update on the rezpegaldesleukin programme or news on the Eli Lilly litigation — the two variables that currently divide the Street most sharply.
See the live data behind this article on ORTEX.
Open NKTR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
